Kestrel Therapeutics

The company's scientific strategy is based on a deep physical understanding of drug-target interactions to create precise and lethal treatments against cancer cells. Recent patents filed by Kestrel describe new GTPase KRAS mutant inhibitors that have shown activity in suppressing cancer cell proliferation and inhibiting key signaling pathways in preclinical studies. Based at the Pagliuca Harvard Life Lab in Allston, MA, Kestrel Therapeutics is part of a vibrant biotech ecosystem and leverages a data-driven approach in its research and development.

Founder, President, and CEO Frank Haluska, MD, PhD, brings extensive experience from previous leadership roles at Anchiano Therapeutics and ARIAD Pharmaceuticals, as well as academic positions at Harvard Medical School and Massachusetts General Hospital. His background includes a BA from Harvard University and dual M.D. and Ph.D. degrees from the University of Pennsylvania. The company is backed by prominent investors including Pfizer Ventures, Cormorant Asset Management, Santé Ventures, and S32, having raised capital through several funding rounds to advance its pipeline.